CPT code 67027 describes a surgical ophthalmology procedure in which a portion of the vitreous humor is removed and a slow‑release drug implant is placed into the vitreous cavity to deliver medication directly to the posterior segment of the eye, commonly used for conditions like cytomegalovirus retinitis. This code matters nationally because it represents a specialized, resource‑intensive intraocular intervention that intersects surgical, ophthalmic, and pharmaceutical billing considerations and can influence access to advanced local drug delivery therapies.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the procedure, typical sites of service, and the billing framework for CPT code 67027. The publication outlines common modifiers and typical service settings, summarizes payer coverage patterns where available, and highlights areas relevant for billing teams and policy analysts, such as coding specificity and clinical indications. Data not available in the input is noted where applicable. This summary equips revenue cycle and clinical staff with the foundational information needed to interpret and apply CPT code 67027 in national billing and policy contexts.